DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, Harvie BM, Kinneally TL, Yeh SM, McCarthy DA, Koepsell H, Vallon V, Pollock C, Panchapakesan U, Forbes JM.
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.
Sci Rep 2016;
6: 26428
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.